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We thank Dr. Henry and colleagues for their interest
in our study on the mode of death in the RELAX-AHF
(Efﬁcacy and Safety of Relaxin for the Treatment of
Acute Heart Failure) study of serelaxin in acute heart
failure (1). The authors provide very interesting data
from their own laboratory on the possible role of
serelaxin in modulating cardiac ﬁbrosis, myocyte
hypertrophy, and cardiac conduction (2) and specu-
late that these mechanisms may be potential expla-
nations for the reduction in sudden death and fatal
stroke observed with serelaxin treatment in the
RELAX-AHF study.
As the authors point out, there are substantial
differences in dose, duration of exposure, and disease
state between their experimental model and our
clinical trial results, making it difﬁcult to draw any
deﬁnitive conclusions about the possible role of these
mechanisms in our ﬁndings. Importantly, however,
their data do underscore the pleiotropic nature of the
biological effects of relaxin (3), which may in part
explain the favorable impact of serelaxin therapy onclinical outcomes (4) and end-organ function (5) seen
in the RELAX-AHF study. As noted, the ongoing
RELAX-AHF2 (Efﬁcacy, Safety and Tolerability of
Serelaxin When Added to Standard Therapy in AHF)
study (NCT01870778) will provide more deﬁnitive
data on the efﬁcacy of serelaxin in acute heart failure.
The interesting data provided by Dr. Henry and col-
leagues suggest additional avenues of research for the
potential role of serelaxin in the treatment of car-
diovascular disease.*G. Michael Felker, MD, MHS
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